Regulatory considerations for manufacturing, packaging and labeling in US MCQs With Answer

Regulatory considerations for manufacturing, packaging and labeling in US MCQs With Answer

This quiz set is designed for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics (MRA201T) and focuses on US regulatory requirements for manufacturing, packaging and labeling. Questions emphasize current Good Manufacturing Practices (cGMP), 21 CFR requirements, labeling rules, packaging controls, serialization, stability, recalls and quality system responsibilities. The aim is to deepen understanding of practical compliance issues — from container-closure integrity and tamper-evident features to FDA labeling mandates, Drug Supply Chain Security Act (DSCSA) and adverse event reporting — so students can apply regulatory principles in pharmaceutical development, production and quality assurance.

Q1. Which CFR part primarily defines current Good Manufacturing Practice (cGMP) requirements for finished pharmaceuticals in the United States?

• 21 CFR Part 11
• 21 CFR Part 210 and Part 211
• 21 CFR Part 820
• 21 CFR Part 312

Correct Answer: 21 CFR Part 210 and Part 211

Q2. Under US regulations, which unit within a pharmaceutical firm is primarily responsible for ensuring that each batch is manufactured and tested in compliance with established procedures and release criteria?

• Marketing department
• Quality unit (Quality Assurance/Quality Control)
• Regulatory affairs
• Research and development

Correct Answer: Quality unit (Quality Assurance/Quality Control)

Q3. The Drug Supply Chain Security Act (DSCSA) primarily requires which of the following for prescription drug packages?

• Single global expiration date for all distributors
• Serialization and product tracing to enhance supply chain security
• Removal of National Drug Code (NDC) numbers
• Mandatory child-resistant packaging for all Rx drugs

Correct Answer: Serialization and product tracing to enhance supply chain security

Q4. Which FDA regulation governs the content and format for prescription drug labeling, including required statements such as indications, dosage, and contraindications?

• 21 CFR Part 201
• 21 CFR Part 211
• 21 CFR Part 600
• 21 CFR Part 4

Correct Answer: 21 CFR Part 201

Q5. For an over-the-counter (OTC) drug sold in the United States, which labeling element is mandatory and must follow a standardized format?

• Drug Facts panel
• Biological license number
• Investigational use only statement
• Pre-approval marketing claims

Correct Answer: Drug Facts panel

Q6. Which of the following is a required practice for sterile product manufacturing to demonstrate control of particulate and microbial contamination?

• Use of only automated filling lines without environmental monitoring
• Environmental monitoring and controlled cleanroom classification
• Disinfection once per month
• Relying solely on final product sterility testing without process controls

Correct Answer: Environmental monitoring and controlled cleanroom classification

Q7. What is the primary regulatory purpose of a “lot number” on pharmaceutical packaging?

• To provide marketing information to consumers
• To identify and facilitate traceability of a specific batch for recall and investigation
• To indicate price and distributor data
• To denote patent expiration

Correct Answer: To identify and facilitate traceability of a specific batch for recall and investigation

Q8. Which labeling statement is required on a prescription drug container or carton to indicate distribution restrictions in the United States?

• WARNING: May cause drowsiness
• For prescription use only (Rx only)
• Not evaluated for pediatric use
• Store below 30°C

Correct Answer: For prescription use only (Rx only)

Q9. Under 21 CFR Part 211, which of the following is a required control related to packaging and labeling operations?

• Use of verbal instructions only for labeling operators
• Procedures for removal of outdated labels and prevention of label mix-ups
• Label printing may be performed without documentation
• Label reconciliation is optional

Correct Answer: Procedures for removal of outdated labels and prevention of label mix-ups

Q10. Which regulatory mechanism requires pharmaceutical manufacturers to report adverse events and product problems to the FDA?

• Good Laboratory Practice (GLP)
• MedWatch (FDA Adverse Event Reporting System)
• Patent Office reporting
• International Nonproprietary Name (INN) registry

Correct Answer: MedWatch (FDA Adverse Event Reporting System)

Q11. For stability labeling, which term refers to the date up to which a manufacturer guarantees full potency and safety of a drug product under specified storage conditions?

• Beyond-use date
• Expiration date
• Manufacture date
• Stability initiation date

Correct Answer: Expiration date

Q12. The Poison Prevention Packaging Act (PPPA) in the US primarily requires which of the following for certain oral pharmaceutical products?

• Mandatory blister packs for all medications
• Child-resistant packaging for household substances and many prescription drugs
• Removal of unit-dose packaging options
• Standardized cap colors across manufacturers

Correct Answer: Child-resistant packaging for household substances and many prescription drugs

Q13. What is the FDA’s classification system for recalls that describes the relative degree of health hazard presented by a product defect?

• Type I, II, III recalls
• Class I, II, III recalls
• Tier A, B, C recalls
• Level 1, 2, 3 recalls

Correct Answer: Class I, II, III recalls

Q14. Which of the following packaging features is most directly intended to deter product adulteration and allow detection of tampering?

• Instruction leaflet inside carton
• Tamper-evident seals and closures
• Opaque secondary packaging
• Barcode placement only on outer case

Correct Answer: Tamper-evident seals and closures

Q15. Under 21 CFR Part 11, what is the main regulatory focus relevant to electronic records and signatures in pharmaceutical manufacturing and labeling systems?

• Formatting of printed labels
• Requirements for validated electronic recordkeeping, audit trails, and secure electronic signatures
• Prohibition of any electronic systems in manufacturing
• Exemption of clinical data from electronic controls

Correct Answer: Requirements for validated electronic recordkeeping, audit trails, and secure electronic signatures

Q16. Which of the following is required on an Rx drug label per FDA guidance to help healthcare providers avoid medication errors related to drug name confusion?

• Use of proprietary name only without generic name
• Prominent display of both proprietary (brand) and established (generic) name where applicable
• Inclusion of marketing slogans
• Listing only the active ingredient concentration without name

Correct Answer: Prominent display of both proprietary (brand) and established (generic) name where applicable

Q17. When validating packaging operations for a blister-packaged oral solid, which validation activity is most critical to ensure product stability and dose accuracy?

• User preference surveys for blister design
• Container-closure integrity testing and process validation for fill weight and sealing
• Color matching of packaging artwork
• Shelf placement testing in retail stores

Correct Answer: Container-closure integrity testing and process validation for fill weight and sealing

Q18. Which labeling requirement is specific to biological products (such as vaccines) and administered in clinical settings, beyond standard drug labeling?

• Inclusion of a National Drug Code (NDC)
• Lot number and expiration date for traceability and adverse event investigations
• Instructions for retail display
• Marketing authorization holder phone number only

Correct Answer: Lot number and expiration date for traceability and adverse event investigations

Q19. The FDA’s “Unique Device Identifier” (UDI) requirement applies primarily to which product category and how does it intersect with packaging/regulatory controls?

• Prescription drugs with barcodes for National Drug Code (NDC)
• Medical devices; UDI must be on device labels and packaging to improve traceability and recalls
• Cosmetic products only, for ingredient tracking
• Dietary supplements subject to DSCSA

Correct Answer: Medical devices; UDI must be on device labels and packaging to improve traceability and recalls

Q20. Which practice is essential when a manufacturer changes label artwork or ingredients, to remain compliant with FDA expectations before distribution?

• Immediately distribute updated product without documentation to meet market demand
• Perform change control, update labeling documentation, and where required, notify FDA or submit supplements for approval
• Only update the marketing brochures and ignore label files
• Maintain the old labels and add a handwritten note to cartons

Correct Answer: Perform change control, update labeling documentation, and where required, notify FDA or submit supplements for approval

Download